Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial

References

• World Health Organization. [accessed 2023 May 12]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–15. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–1785. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• Notarte KI, Guerrero‐Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, MdSR K, Pastrana A, Juszczyk G, Torrelles JB, et al. Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: a systematic review. J Med Virol. 2022;94:2939–2961. doi:10.1002/jmv.27688.
   PubMed Web of Science ®Google Scholar
• Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect. 2022;84(2):248–288. doi:10.1016/j.jinf.2021.09.013.
   PubMed Web of Science ®Google Scholar
• Dimeglio C, Migueres M, Mansuy J-M, Saivin S, Miedougé M, Chapuy-Regaud S, Izopet J. Antibody titers and breakthrough infections with Omicron SARS-CoV-2. J Infect. 2022;84(4):e13–e15. doi:10.1016/j.jinf.2022.01.044.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66.
   PubMed Web of Science ®Google Scholar
• Lehtoranta L, Pitkäranta A, Korpela R. Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1289–1302. doi:10.1007/s10096-014-2086-y.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - a systematic review. Vaccine. 2018;36(2):207–213. doi:10.1016/j.vaccine.2017.08.069.
   PubMed Web of Science ®Google Scholar
• Spacova I, Patusco R, Lebeer S, Jensen MG. Influence of biotic interventions on the immune response to vaccines in young and older adults. Clin Nutr. 2023;42(2):216–226. doi:10.1016/j.clnu.2023.01.001.
   PubMed Web of Science ®Google Scholar
• Boge T, Rémigy M, Vaudaine S, Tanguy J, Bourdet-Sicard R, van der Werf S. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine. 2009;27(41):5677–5684. doi:10.1016/j.vaccine.2009.06.094.
   PubMed Web of Science ®Google Scholar
• Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2012;107(6):876–884. doi:10.1017/S000711451100420X.
   PubMed Web of Science ®Google Scholar
• Bosch M, Méndez M, Pérez M, Farran A, Fuentes MC, Cuñé J. Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. Nutr Hosp. 2012;27(2):504–509. doi:10.1590/S0212-16112012000200023.
   PubMed Web of Science ®Google Scholar
• Nishihira J, Moriya T, Sakai F, Kabuki T, Kawasaki Y, Nishimura M. Lactobacillus gasseri SBT2055 stimulates immunoglobulin production and innate immunity after influenza vaccination in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. Funct Foods Health Dis. 2016;6(9):544–568. doi:10.31989/ffhd.v6i9.284.
   Google Scholar
• Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutr. 2007;23(3):254–260. doi:10.1016/j.nut.2007.01.004.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y, Abreu AT, Nieto-Rufino CD, López-Orduña E, Jiménez-Escobar I, Jiménez-Gutiérrez C, López-Velazquez G, Espadaler-Mazo J. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. doi:10.1080/19490976.2021.2018899.
   PubMed Web of Science ®Google Scholar
• Markewitz R, Pauli D, Dargvainiene J, Steinhagen K, Engel S, Herbst V, Zapf D, Krüger C, Sharifzadeh S, Schomburg B, et al. B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose. Clin Microbiol Infect. 2022;28:S1198-743X(22)00105–7. doi:10.1016/j.cmi.2022.02.028.
   Web of Science ®Google Scholar
• Turner JS, O’Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596(7870):109–113. doi:10.1038/s41586-021-03738-2.
   PubMed Web of Science ®Google Scholar
• Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, Nahass GR, Salomon-Shulman RE, Blacker G, Fazel-Zarandi M, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022;15(5):799–808. doi:10.1038/s41385-022-00511-0.
   PubMedGoogle Scholar
• Rodriguez-Blanque R, Sánchez-García JC, Cobos-Vargas Á, Aguilar Quesada A, Maldonado-Lobón JA, Olivares M, Blanco-Rojo R. Evaluation of the effect of Loigolactobacillus coryniformis K8 CECT 5711 consumption in health care workers exposed to COVID-19. Front Nutr. 2022;9:962566. doi:10.3389/fnut.2022.962566.
   PubMed Web of Science ®Google Scholar
• Fernández-Ferreiro A, Formigo-Couceiro FJ, Veiga-Gutierrez R, Maldonado-Lobón JA, Hermida-Cao AM, Rodriguez C, Bañuelos O, Olivares M, Blanco-Rojo R. Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the immune response of elderly subjects to COVID-19 vaccination: a randomized controlled trial. Nutrients. 2022;14(1):228. doi:10.3390/nu14010228.
   PubMed Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280. doi:10.1038/s41586-021-03777-9.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–869. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8(1):52. doi:10.1186/s13073-016-0300-5.
   PubMed Web of Science ®Google Scholar